IBDEI21E ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,35594,1,3,0)
 ;;=3^Diffuse large B-cell lymphoma, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,35594,1,4,0)
 ;;=4^C83.38
 ;;^UTILITY(U,$J,358.3,35594,2)
 ;;=^5001579
 ;;^UTILITY(U,$J,358.3,35595,0)
 ;;=C83.58^^189^2057^29
 ;;^UTILITY(U,$J,358.3,35595,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35595,1,3,0)
 ;;=3^Lymphoblastic (diffuse) lymphoma, lymph nodes mult site
 ;;^UTILITY(U,$J,358.3,35595,1,4,0)
 ;;=4^C83.58
 ;;^UTILITY(U,$J,358.3,35595,2)
 ;;=^5001589
 ;;^UTILITY(U,$J,358.3,35596,0)
 ;;=C83.78^^189^2057^15
 ;;^UTILITY(U,$J,358.3,35596,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35596,1,3,0)
 ;;=3^Burkitt lymphoma, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,35596,1,4,0)
 ;;=4^C83.78
 ;;^UTILITY(U,$J,358.3,35596,2)
 ;;=^5001599
 ;;^UTILITY(U,$J,358.3,35597,0)
 ;;=C83.18^^189^2057^35
 ;;^UTILITY(U,$J,358.3,35597,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35597,1,3,0)
 ;;=3^Mantle cell lymphoma, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,35597,1,4,0)
 ;;=4^C83.18
 ;;^UTILITY(U,$J,358.3,35597,2)
 ;;=^5001569
 ;;^UTILITY(U,$J,358.3,35598,0)
 ;;=C83.38^^189^2057^23
 ;;^UTILITY(U,$J,358.3,35598,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35598,1,3,0)
 ;;=3^Diffuse large B-cell lymphoma, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,35598,1,4,0)
 ;;=4^C83.38
 ;;^UTILITY(U,$J,358.3,35598,2)
 ;;=^5001579
 ;;^UTILITY(U,$J,358.3,35599,0)
 ;;=C84.68^^189^2057^12
 ;;^UTILITY(U,$J,358.3,35599,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35599,1,3,0)
 ;;=3^Anaplastic large cell lymphoma, ALK-pos, nodes mult site
 ;;^UTILITY(U,$J,358.3,35599,1,4,0)
 ;;=4^C84.68
 ;;^UTILITY(U,$J,358.3,35599,2)
 ;;=^5001659
 ;;^UTILITY(U,$J,358.3,35600,0)
 ;;=C84.78^^189^2057^11
 ;;^UTILITY(U,$J,358.3,35600,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35600,1,3,0)
 ;;=3^Anaplastic large cell lymphoma, ALK-neg, nodes mult site
 ;;^UTILITY(U,$J,358.3,35600,1,4,0)
 ;;=4^C84.78
 ;;^UTILITY(U,$J,358.3,35600,2)
 ;;=^5001669
 ;;^UTILITY(U,$J,358.3,35601,0)
 ;;=C81.08^^189^2057^43
 ;;^UTILITY(U,$J,358.3,35601,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35601,1,3,0)
 ;;=3^Nodular lymphocyte predom Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,35601,1,4,0)
 ;;=4^C81.08
 ;;^UTILITY(U,$J,358.3,35601,2)
 ;;=^5001399
 ;;^UTILITY(U,$J,358.3,35602,0)
 ;;=C81.48^^189^2057^28
 ;;^UTILITY(U,$J,358.3,35602,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35602,1,3,0)
 ;;=3^Lymp-rich classical Hodgkin lymphoma, lymph nodes mult site
 ;;^UTILITY(U,$J,358.3,35602,1,4,0)
 ;;=4^C81.48
 ;;^UTILITY(U,$J,358.3,35602,2)
 ;;=^5001439
 ;;^UTILITY(U,$J,358.3,35603,0)
 ;;=C81.18^^189^2057^44
 ;;^UTILITY(U,$J,358.3,35603,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35603,1,3,0)
 ;;=3^Nodular sclerosis class Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,35603,1,4,0)
 ;;=4^C81.18
 ;;^UTILITY(U,$J,358.3,35603,2)
 ;;=^5001409
 ;;^UTILITY(U,$J,358.3,35604,0)
 ;;=C81.28^^189^2057^36
 ;;^UTILITY(U,$J,358.3,35604,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35604,1,3,0)
 ;;=3^Mixed cellular classical Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,35604,1,4,0)
 ;;=4^C81.28
 ;;^UTILITY(U,$J,358.3,35604,2)
 ;;=^5001419
 ;;^UTILITY(U,$J,358.3,35605,0)
 ;;=C81.38^^189^2057^30
 ;;^UTILITY(U,$J,358.3,35605,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35605,1,3,0)
 ;;=3^Lymphocy depleted class Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,35605,1,4,0)
 ;;=4^C81.38
 ;;^UTILITY(U,$J,358.3,35605,2)
 ;;=^5001429
 ;;^UTILITY(U,$J,358.3,35606,0)
 ;;=C82.98^^189^2057^26
 ;;
 ;;$END ROU IBDEI21E
